Castle Biosciences CSTL 深 沪
已收盘 03-27 16:00:00 美东时间
23.53
-1.170
-4.74%
华盛通- 最 高24.645
- 今 开24.60
- 成交量 29.41万股
- 最 低 23.44
- 昨 收 24.70
- 总市值 7.00亿
- 52周最高 44.28
- 市盈率 静 --
- 换手率 0.99%
- 52周最低 14.59
- 委 比 -97.58%
- 总股本 2973.12万
- 历史最高 107.69
- 量 比 0.97
- 振 幅 4.88%
- 历史最低 9.2601
- 每 手 1
- 风险率 8.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Castle Biosciences To Present New Data Showing DecisionDx-Melanoma Test Refines Mortality Risk Within AJCC Stages For Patients With Cutaneous Melanoma At 2026 AAD Annual Meeting
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee on Cancer (AJCC)
03-27 21:08
Castle Biosciences shares rise; DecisionDx-Melanoma study in 1,868 SEER-linked patients shows 5-year melanoma-specific survival of 96.7% for Class 1A vs 70.0% for Class 2B in T1 tumors
Castle Biosciences shares rise; DecisionDx-Melanoma study in 1,868 SEER-linked patients shows 5-year melanoma-specific survival of 96.7% for Class 1A vs 70.0% for Class 2B in T1 tumors Castle announced an analysis of 1,868 SEER-linked patients with stage I–III cutaneous melanoma evaluating its Decis
03-27 21:07
Sweden's SciBase Q4 sales rise on US, skin barrier growth
Sweden's SciBase Q4 sales rise on US, skin barrier growth Overview Sweden medical technology firm's Q4 net sales rose 45% yr/yr, loss after tax widened Gross margin fell to 63% from 68.5%, impacted by currency and higher input costs Outlook Company did not provide specific financial or operational g
03-13 15:13
Castle Biosciences' i31‑SLNB Test Validates Predictive Accuracy In Melanoma Study, Supports Safe SLNB Avoidance
Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix.NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the
03-09 19:12
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Castle Biosciences presented data at the SSO 2026 Annual Meeting showing that their DecisionDx-Melanoma test accurately predicts sentinel lymph node (SLN) positivity in melanoma patients. The i31-SLNB algorithm combines a 31-gene expression profile with clinicopathologic factors to identify low-risk patients with very low SLN positivity rates (2.6% overall, 1.4% in T1b–T2a tumors) and high recurrence-free survival. These findings support the test...
03-09 11:00
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $44
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from $41 to $44.
02-27 20:42
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Exploring Castle Biosciences's Earnings Expectations
Castle Biosciences (NASDAQ:CSTL) is set to give its latest quarterly earnings r...
02-26 04:01
Exploring Castle Biosciences's Earnings Expectations
Castle Biosciences (NASDAQ:CSTL) is set to give its latest quarterly earnings r...
02-26 04:01
